You are here

  • Home
  • Archive
  • Volume 71, Issue Suppl 3
  • P159 Therapeutic benefit of mepolizumab in the scottish medicines consortium (SMC) restricted sub-population – a post-hoc meta-analysis of phase iib/iii trials

Alerts

Article menu

Download PDFPDF

Asthma Treatments and What Matters to Patients
P159 Therapeutic benefit of mepolizumab in the scottish medicines consortium (SMC) restricted sub-population – a post-hoc meta-analysis of phase iib/iii trials
Free
You need to be signed in to access email alerts. If you have an account log in with your user name and password. If you don't have an account you can just enter your email address in the email box below.
Sign In to Email Alerts with your Email Address